Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

Completed

Conditions studied: Cardiomyopathy, Chronic Kidney Disease, Anemia

In brief

This study examines patients with chronic kidney disease-related anemia and measures changes in the metabolism of the heart using FDG/PET scanning, before and 6 months after their health-care provider has initiated anemia management therapy with the FDA-approved drug darbepoetin alfa (Aranesp), which is approved for chronic kidney disease-related anemia. The investigators hypothesize that the heart has abnormal metabolism with the anemia of chronic kidney disease but this improves after correction of this anemia with darbepoetin alfa.

Key facts

Study ID
NCT00883415
Run by
University of Maryland, Baltimore
People needed
20
Starts
2008-05-01
Expected to finish
2012-11-01
Last updated by the study team
2020-05-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.